How a Bold Thinker Helped Introduce Chemotherapy Combinations to Cancer Therapy
When Vincent T. DeVita Jr, MD, began testing a cocktail of four chemotherapies against advanced Hodgkin disease back in 1964, the disease was uniformly fatal.
A Time of Hope in Lung Cancer
Leading researchers described several areas of significant advances during the 9th Annual New York Lung Cancer Symposium, a daylong conference that Physicians' Education Resource hosted November 8.
The Evolving Treatment Landscape in Advanced Melanoma
Metastatic melanoma is associated with a poor prognosis, but recent breakthroughs in tumor biology and immune regulation have led to the development of agents that could change clinical practice.
A New World of Targeted Therapies for HER2-Positive Breast Cancer Takes Shape
When added to standard chemotherapy, trastuzumab not only dramatically improved disease-free survival rates for patients with metastatic disease, but also resulted in a clear survival advantage unprecedented for most treatments of metastatic breast cancer.
The New BRCA1/2 Landscape
As one of the most significant predictors of hereditary breast and ovarian cancer, the BRCA1/2 genes have become the poster child for genetic testing, thrust into the limelight by a high-profile court battle and a celebrity's disclosure.
Molecular Markers Emerge in the Diagnosis of Thyroid Cancer
Although prognostic biomarkers have become increasingly important in the treatment of many types of cancer, no such markers have yet been identified and validated for thyroid cancer.
How Is Treatment Changing for Patients With Cervical Cancer? Three Experts Weigh In
Dr. Richard T. Penson, Dr. Bradley J. Monk, and Dr. Krishnansu S. Tewari discuss the evolution of cervical cancer treatment over the past five years.
Patient-Contributed Tumor Genetics Data: A Pathway to Better Drug Development?
Developing companion diagnostics has several associated challenges related to cost, access to samples, and clinical trial recruitment.
Research and Policy Paradigms Must Consider Patients' Assessments of Relevant Goals and Outcomes
What patients with cancer perceive as relevant clinical outcomes, and how these outcomes are assessed, is important in the provision of routine care and in the arena of clinical trials.
Three Experts Discuss the Use of Cetuximab in Head and Neck Cancers
Cetuximab is the only FDA-approved EGFR inhibitor for the treatment of squamous cell carcinoma of the head and neck.
The Emerging "N-of-1" Model:Clinical Relevance of Individualized Tumor Profiling Grows in Research Programs
Molecular studies are increasingly utilized to develop an individual
therapeutic approach based on abnormalities present in the setting of
uncommon/rare cancers or in specific clinical situations where it is
virtually certain that formal regulatory-based trials will never be
Sotigalimab/Pembrolizumab Combo Continues to Show Clinical Activity in Frontline Melanoma
Dr. Halmos on Trastuzumab Deruxtecan in NSCLC
Dr. Kris on Immunotherapy in NSCLC Without Driver Mutations
Checkpoint Inhibitor Challenges Warrant Consideration for a Targeted Approach in NSCLC
2 Clarke DriveSuite 100Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.